



Date 20 December 2016

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

MARKET CAPITALISATION - UPDATE

The Company wishes to advise that having satisfied the \$50 million market capitalisation criteria relating to Performance Shares, the Company has converted and issued 10m ordinary shares to 4 shareholders.

Two of the 4 shareholders are directors of the Company (Drs Graham Kelly and Ian Dixon); the shares remain unlisted and are subject to escrow until August 2018.

The updated issued capital of the company is as follows:

| | | Unlisted | Listed |
|---|-------------------------------------|------------|------------|
| Listed Fully Paid Ordinary Shares | | | 33,560,000 |
| Unlisted Ordinary shares | Subject to escrow until 08 Jan 2017 | 464,750 | |
| Unlisted Ordinary shares | Subject to escrow until 01 Apr 2017 | 4,261,214 | |
| Unlisted Ordinary shares | Subject to escrow until 08 Aug 2018 | 46,885,465 | |
| Unlisted Options \$0.30 Expiry 28/02/21 | Subject to escrow until 08 Aug 2018 | 18,950,358 | |
| Unlisted Options \$0.30 Expiry 28/02/21 | Subject to escrow until 08 Jan 2017 | 357,500 | |
| Unlisted Options \$0.30 Expiry 28/02/21 | Subject to escrow until 01 Apr 2017 | 3,277,858 | |

Listed Shares: 33,560,000

Unlisted Shares: 51,611,429

Unlisted Options: 22,585,716

Phillip Hains
Company Secretary

About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the

major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

INVESTOR AND MEDIA ENQUIRIES:
E: info@noxopharm.com

Prue Kelly
T: + 61 2 9144 2223

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.